Genevieve Leveille, Venture Partner of BioLife and Co-Chair of the TechUK DLT Working Group explores how current advances in DLT will improve the world’s biomedical supply chains when it comes to life sciences health care
The way health services are delivered is changing and not a moment too soon for the world’s ailing healthcare systems. Issues of patient data security, meeting agreed standards of healthcare and ensuring better health outcomes for all people everywhere have brought some of the brightest minds on the planet together at this crucial time, to solve the crisis. The BioLife team is at the forefront of the move toward lowering the costs of intricate care.
As BioLife begins to improve access to high-end biomedical services worldwide, there will be a noticeable shift in the way health is managed and treated. BioLife, through its digital ecosystem, integrates the world’s major life science resources to underpin lifetime patient care and ensure global liquidity for the bioscience industry.
Yuelin Liu, Chairman of the Tinjoy Health Group, Executive Director of the China Overseas Chinese Merchants Association and Chairman of Shenzhen One Belt and One Road Investment Development Group started his business in 2007 and has made many advances in the life sciences industry including as the creator of BioLife.
Founded on digital ledger technology (DLT) as a consortium chain of ACChain, BioLife digitises assets and handles private records for patients, investors and owners of global biomedical resources. Patients can create a personal electronic health record (EHR) and access high-end health product and service suppliers. Biomedical resources are digitised, and traceability is maintained throughout the supply chain as trade in digital assets between resource owners and patients takes place. Immutable peer-to-peer transactions occur on the BioLife chain when agreements trigger linked smart contracts.
These new technologies can support people in taking more responsibility for their own health. Waste is reduced within the system as biomedical resources are tracked end-to-end. Overall, the introduction of the BioLife ecosystem creates more productivity within the health systems of the world. Research and the development of new treatments are well supported through open sharing and better treatments without duplication can be produced faster. Treatments are becoming more personalised.
The BioLife platform serves as a safe, reliable, efficient and economical foundation for a thriving biosciences community. Products, services, personal data and assets relevant to life sciences health care are being digitised. Patients can obtain authenticated pharmaceutical drugs and biomedical services and receive access to a credit ledger from asset owners.
BioLife providers include pharmaceutical companies, health service organisations, equipment manufacturers and research institutions. As patients purchase health services on the BioLife Service Platform, the relevant health data is accessed only through a private key and transmitted peer-to-peer, ensuring privacy and security.
As a decentralised healthcare delivery system, BioLife is poised with advantage in the coming establishment of widespread high-capacity, low-latency 5G networks planned for deployment in 2019. Early investors in the BioLife ecosystem will benefit from these deployments, which will support acceleration in the digitisation of distributed, local health resources worldwide.
The BioLife service platform opens a transparent marketplace for a wealth of customised biomedical treatments and therapies. BIOT, as the internal fuel token of BioLife, enables trade in biomedical resources as digital assets, reducing cross-border payment costs and risks. Contributors and investors are able to acquire, maintain and access intricate health care within a safe and secure exchange system. BIOT is structured in a way that supports the entire BioLife digital ecosystem and increases liquidity within the biomedical industry.
The BioLife community is occupied by three types of members: clients (patients and their families), providers (health services practitioners, biomedical researchers, health service institutions, government agencies and non-profits), and developers (programmers and software engineers). As bioscience develops biological solutions to sustain, restore and improve quality of life for humans, plants and animals in our world, the BioLife community seeks to establish a service channel of traceability, security, convenience and confidentiality.
BioLife’s resource providers include Swiss Serolab® of Leukerbad Wellness Management Group Ltd. The first enterprise to BioLife, Swiss Serolab® provides over 80 types of medicines and own more than 1,000 bioscience patents covering areas from anti-ageing to major illness precaution. Enshi Tinjoy Bio-Technology Co., Ltd., another resource provider on the BioLife chain, is a high-tech enterprise specialising in micro-ecological health. Shenzhen Dongchen Pharmaceutical Holdings Ltd., whose main business includes pharmaceutical precision retail, big data applications, health management, and cross-border e-commerce of big health will integrate the chain pharmacy resources and adopt a model of “direct mining and self-operating + offline experience + health consultants” to provide clients with a number of value-added services. Guangzhou Zhongxin Gene Medical Technology Co., Ltd., a genetic wholly-owned enterprise with a mission to “take genetic technology as the core, with mobile intelligent monitoring of the Internet of things (IoT) platform to support and implement dynamic monitoring” is also among the first resource providers to join BioLife, with benefits to patients and the industry itself.
BioLife’s resource providers include Swiss Serolab® of Leukerbad Wellness Management Group Ltd. The first enterprise to BioLife, Swiss Serolab® provide over 80 types of medicines and own more than 1,000 bioscience patents covering areas from anti-ageing to major illness precaution. Resource provider Enshi Tinjoy Bio-Technology Co., Ltd. is a high-tech enterprise specializing in micro-ecological health. Shenzhen Dongchen Pharmaceutical Holdings Ltd., whose main business includes pharmaceutical precision retail, big data applications, health management, and cross-border ecommerce of big health will provide clients with a number of value-added services. Guangzhou Zhongxin Gene Medical Technology Co., Ltd., a genetic wholly-owned enterprise with a mission to “take genetic technology as the core is also among the first resource providers to join BioLife, with benefits to patients and the industry itself.
As BioLife integrates our world’s life science resources into one digital ecosystem, investors in BioLife have all the evidence of the value of their investments at their fingertips. It is time to reduce the costs of intricate care for Your Body, Your Health and Your Life.
Social media links
Please note: this is a commercial profile
BioLife and Co-Chair of the TechUK DLT Working Group
Editor's Recommended Articles
Must Read >> Protecting and promoting U.S. agricultural health